In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Ghassan Abou-Alfa argues that regorafenib should be the standard second line therapy for hepatocellular carcinoma (HCC).
Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER
© 2017 Imedex, LLC.
Advertisement